Applying Expert Knowledge for Nitrosamine Carcinogenicity Assessment

Join us for an insightful webinar featuring Dr. Roustem Saiakhov, Dr. Suman Chakravarti, and Dr. Krystle Reiss from MultiCASE!
We are excited to introduce a groundbreaking Nitrosation Module for hazard characterization within QSAR Flex. This webinar covers a comprehensive review of the transformative year following the adoption of the Carcinogenic Potency Categorization Approach (CPCA) framework. This regulatory-endorsed method aims to establish a recommended Acceptable Intake limit for NDSRIs by identifying substructural features that influence potency categories. We also provide an overview of the general scope of CPCA, including categorical definitions based on potency scores. Key aspects of the expert review process are highlighted, with a focus on the preliminary hazard characterization of nitrosamine formation from active pharmaceutical ingredients (APIs) and route of synthesis. Additionally, we discuss the latest developments in the QSAR Flex nitrosamine suite, including an introduction to the new QSAR Flex Nitrosamine Formation Module.

[@jkgupta3334]

Please load more vedios related ich m7, nitroso amine, qsar approach

[@eswarguntu8953]

Sir/Madam, I am very new to nitrosamine and mutagenic, can you please help me to gain knowledge regarding this concepts..

[@eswarguntu8953]

Please..